Back to Journals » ClinicoEconomics and Outcomes Research » Volume 11

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

Total article views   HTML views PDF downloads Totals
9,815 Dovepress* 8,880+ 1,154 10,034
PubMed Central* 935 237 1,172
Totals 9,815 1,391 11,206
*Since 8 November 2019
Total mentioned Facebook Delicious Reddit Twitter Others
7 0 0 0 2 5

View citations on PubMed and Google Scholar